Thermo Fisher Scientific (TMO) Lands Spotlight In Fast Growing Cell And Gene Therapy CRO Market

What happened: Thermo Fisher Scientific ($TMO) was highlighted as a leading player in the cell and gene therapy CRO market, recognized among providers offering integrated clinical trial services for advanced therapies. Key numbers: Q3 2026 sales of US$12.1b, net income of US$1.7b, basic EPS of US$4.65 from continuing operations. Article cites a $687 fair value. Why it matters: The article says the spotlight fits Thermo Fisher's existing narrative, which leans on pharma and biotech demand, portfolio deals like Clario, and expansion in bioproduction and AI enabled data platforms. Market: +1.6% today ($704.15), +19.1% YTD, 0.8x vol — as of 08:00 UTC

Thermo Fisher Scientific ($TMO) was highlighted as a leading player in the cell and gene therapy CRO market, recognized among providers offering integrated clinical trial services for advanced therapies.

The article says the spotlight fits Thermo Fisher's existing narrative, which leans on pharma and biotech demand, portfolio deals like Clario, and expansion in bioproduction and AI enabled data platforms. Market: +1.6% today ($704.15), +19.1% YTD, 0.8x vol — as of 08:00 UTC